The HarbourVest team has been investing in the private markets for over 30 years, gaining invaluable expertise and developing long-term relationships with sought-after partners. Our approach is characterized by consistency and continuity while also adapting to meet client needs.  Over the years, we have continually identified opportunities to provide early access to the evolving private equity landscape – secondary investing (since 1986), Europe market (since 1984), Asia market (since 1984) – and expanded our local teams around the globe.

Horizon has been ranked as one of the fastest growing biotechnology companies in Europe by Deloitte with staff of more than 200 people spread across R&D, operations and commercial functions and accommodated within a 80,000 sq. ft. of state-of-the-art facilities in Cambridge, MA, USA. The company has grown rapidly and now has a customer base approaching 1,000 organisations including major pharmaceutical, biotech and diagnostic companies as well as leading academic research centres. Horizon was named the 2014 European Mediscience Emerging Star Award following its £68.6 million IPO on the AIM market of the LSE and an all-time record for a Life Science company.

Shares is the UK's leading investment magazine. Published weekly, Shares provides its readers with a wealth of investment information covering areas such as large, mid and small cap stocks, commodities, bonds, funds, forex, ETFs, ISAs and much more and enjoyed by 15,000 readers across print, web and mobile.